
Bicycle Therapeutics PLC
NASDAQ:BCYC

Operating Margin
Bicycle Therapeutics PLC
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
UK |
![]() |
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
602.8m USD |
-948%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
337.9B USD |
30%
|
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
165.8B USD |
25%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
141.4B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
130.4B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.9B USD |
29%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Bicycle Therapeutics PLC
Glance View
Bicycle Therapeutics PLC, a pioneering force in biotechnology, was founded on a unique vision to transform medicine using a novel class of therapeutics known as Bicycles®. These are synthetic short peptides that combine the pharmacological capabilities of biologics with the manufacturing and distribution advantages of small molecules. The company's scientific ingenuity, originating from Cambridge, UK, has enabled it to engineer and develop a pipeline of drugs targeting areas with significant unmet medical needs, primarily in oncology and other severe diseases. Bicycle leverages its distinctive platform technology to design therapeutic candidates that offer high specificity and affinity, focusing on targets that have traditionally been challenging for conventional biologics and small molecules. Monetizing this innovative biotechnology hinges on Bicycle's strategic partnerships and collaborations with major pharmaceutical firms. These alliances allow the company to amplify its reach while sharing the risks and costs associated with drug development. By licensing their Bicycle® technology and therapeutic candidates to larger entities, Bicycle benefits from milestone payments and royalty streams, creating a sustainable revenue model. The company's revenue stream is thus a blend of upfront payments for access to their platform technology and the potential downstream success of these partners in developing and commercializing new therapeutic agents. Their unique approach and strong collaboration network position Bicycle Therapeutics at the forefront of next-generation drug discovery, striving to reshape treatment paradigms across multiple therapeutic areas.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Bicycle Therapeutics PLC's most recent financial statements, the company has Operating Margin of -948%.